These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 36590263)

  • 21. Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography.
    Young G; Yonekawa KE; Nakagawa PA; Blain RC; Lovejoy AE; Nugent DJ
    Blood Coagul Fibrinolysis; 2007 Sep; 18(6):547-53. PubMed ID: 17762530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical use of Fondaparinux: A synthetic heparin pentasaccharide.
    Zhang Y; Zhang M; Tan L; Pan N; Zhang L
    Prog Mol Biol Transl Sci; 2019; 163():41-53. PubMed ID: 31030756
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How to effectively manage the event of bleeding complications when using anticoagulants.
    Sartori MT; Prandoni P
    Expert Rev Hematol; 2016 Jan; 9(1):37-50. PubMed ID: 26573697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reversing anticoagulants both old and new.
    Warkentin TE; Crowther MA
    Can J Anaesth; 2002; 49(6):S11-25. PubMed ID: 12557411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A neutralizable dimeric anti-thrombin aptamer with potent anticoagulant activity in mice.
    Nagano M; Kubota K; Sakata A; Nakamura R; Yoshitomi T; Wakui K; Yoshimoto K
    Mol Ther Nucleic Acids; 2023 Sep; 33():762-772. PubMed ID: 37621412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis.
    Potze W; Arshad F; Adelmeijer J; Blokzijl H; van den Berg AP; Meijers JC; Porte RJ; Lisman T
    PLoS One; 2014; 9(2):e88390. PubMed ID: 24505487
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pentasaccharides for the prevention of venous thromboembolism.
    Dong K; Song Y; Li X; Ding J; Gao Z; Lu D; Zhu Y
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD005134. PubMed ID: 27797404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heparin pentasaccharide.
    Gallus AS; Coghlan DW
    Curr Opin Hematol; 2002 Sep; 9(5):422-9. PubMed ID: 12172461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis.
    Kalicki RM; Aregger F; Alberio L; Lämmle B; Frey FJ; Uehlinger DE
    Thromb Haemost; 2007 Dec; 98(6):1200-7. PubMed ID: 18064314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux).
    Samama MM; Gerotziafas GT
    Thromb Res; 2003 Jan; 109(1):1-11. PubMed ID: 12679126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and experimental experience with factor Xa inhibitors.
    Viles-Gonzalez JF; Gaztanaga J; Zafar UM; Fuster V; Badimon JJ
    Am J Cardiovasc Drugs; 2004; 4(6):379-84. PubMed ID: 15554723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pentasaccharides for the treatment of deep vein thrombosis.
    Brandao GM; Junqueira DR; Rollo HA; Sobreira ML
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011782. PubMed ID: 29199766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers.
    Bijsterveld NR; Moons AH; Boekholdt SM; van Aken BE; Fennema H; Peters RJ; Meijers JC; Büller HR; Levi M
    Circulation; 2002 Nov; 106(20):2550-4. PubMed ID: 12427650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic review of fondaparinux for heparin-induced thrombocytopenia: When there are no randomized controlled trials.
    Linkins LA; Hu G; Warkentin TE
    Res Pract Thromb Haemost; 2018 Oct; 2(4):678-683. PubMed ID: 30349886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A rare case of fondaparinux-induced major bleeding in postmenopausal woman prescribed for non-ST segment elevation Ml.
    Tandon VR; Sharma S; Mahajan S; Mahajan A; Khajuria V
    J Midlife Health; 2013 Oct; 4(4):241-3. PubMed ID: 24381468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A non-anticoagulant synthetic pentasaccharide reduces inflammation in a murine model of kidney ischemia-reperfusion injury.
    Frank RD; Holscher T; Schabbauer G; Tencati M; Pawlinski R; Weitz JI; Mackman N
    Thromb Haemost; 2006 Dec; 96(6):802-6. PubMed ID: 17139376
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extended Physicochemical Characterization of the Synthetic Anticoagulant Pentasaccharide Fondaparinux Sodium by Quantitative NMR and Single Crystal X-ray Analysis.
    Wildt W; Kooijman H; Funke C; Üstün B; Leika A; Lunenburg M; Kaspersen F; Kellenbach E
    Molecules; 2017 Aug; 22(8):. PubMed ID: 28817073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fondaparinux: basic properties and efficacy and safety in venous thromboembolism prophylaxis.
    Bauer KA
    Am J Orthop (Belle Mead NJ); 2002 Nov; 31(11 Suppl):4-10. PubMed ID: 12463577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neutralizing the anticoagulant activity of ultra-low-molecular-weight heparins using N-acetylglucosamine 6-sulfatase.
    Zhou X; Li L; Linhardt RJ; Liu J
    FEBS J; 2013 May; 280(10):2523-32. PubMed ID: 23374371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.